Enhanced NF-E2-related factor 2 (NRF2) signaling through genetic manipulation of the pathway in these mice led to the prevention of hepatic steatosis, dyslipidemia, and insulin resistance by regulating hepatic lipogenic pathways and restoration of the hepatic fatty acid profile to the levels seen in control mice [3]. The gene discussed is NFE2L2; the disease is Hepatic steatosis.